Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Oncolytic viruses encoding bispecific antibodies for the treatment of ovarian cancers

EF 2021-22

Résumé
Ovarian cancer (OCa) has the highest mortality rate of all gynecologic cancers. Despite extensive testing of cancer therapies in preclinical and clinical trials, there have been no new treatments that significantly lengthen survival of OCa patients in more than 30 years. Currently, surgical resection in combination with chemotherapy provides the only potential long-term cure for OCa, however most women experience cancer recurrence within a few years due to drug resistance. There is a clear unmet need for developing tailored and more effective treatments for OCa. One of the most active areas of research to overcome treatment resistance is the use of combinatorial approaches aimed at stimulating the patient’s immune system to fight against cancer cells while also inducing a potent and selective toxic effect in the tumor. Successful execution of this project will lead to the generation of a oncolytic virus (OV) platform equipped with bispecific T-cell engagers (BiTEs) that is suited not only to kill OCa cells but also to sensitize the tumor environment to the killing activity of immune cells while remaining safe. We expect that the combination of virus-based immunotherapy and therapeutic cargoes expressed from the virus will be an effective two-pronged attack that enhances direct killing of cancer cells. This should indirectly break the tolerance of the patient’s immune system for the ovarian tumor leading to a novel and potentially more effective therapeutic approach for women with OCa.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
475262
Name
Vallati Sydney C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Oncolytic viruses encoding bispecific antibodies for the treatment of ovarian cancers
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bispecific T-Cell Engager; Cancer Immunotherapy; Cancer-Associated Fibroblasts (Caf); Epidermal Growth Factor Receptor (Egfr); Fibroblast Activation Protein (Fap); Oncology; Oncolytic Virus; Ovarian Cancer
Abstract
<html> <head> </head> <body> <span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none"><font color="rgb(0, 0, 0)" face="Verdana, Arial, Helvetica, sans-serif" size="12.8px">Ovarian cancer (OCa) has the highest mortality rate of all gynecologic cancers. Despite extensive testing of cancer therapies in preclinical and clinical trials, there have been no new treatments that significantly lengthen survival of OCa patients in more than 30 years. Currently, surgical resection in combination with chemotherapy provides the only potential long-term cure for OCa, however most women experience cancer recurrence within a few years due to drug resistance.</font></span><font color="rgb(0, 0, 0)" face="Verdana, Arial, Helvetica, sans-serif" size="12.8px"><br align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"><span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none">There is a clear unmet need for developing tailored and more effective treatments for OCa. One of the most active areas of research to overcome treatment resistance is the use of combinatorial approaches aimed at stimulating the patient&#8217;s immune system to fight against cancer cells while also inducing a potent and selective toxic effect in the tumor. Successful execution of this project will lead to the generation of a oncolytic virus (OV) platform equipped with bispecific T-cell engagers (BiTEs) that is suited not only to kill OCa cells but also to sensitize the tumor environment to the killing activity of immune cells while remaining safe. We expect that the combination of virus-based immunotherapy and therapeutic cargoes expressed from the virus will be an effective two-pronged attack that enhances direct killing of cancer cells. This should indirectly break the tolerance of the patient&#8217;s immune system for the ovarian tumor leading to a novel and potentially more effective therapeutic approach for women with OCa.</span></font> </body> </html>
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vallati, Sydney C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~